Results 51 to 60 of about 129,195 (289)
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Whole-genome approach implicates
Human Genomics, 2009 Carboplatin is a chemotherapeutic agent used in the management of many cancers, yet treatment is limited by resistance and toxicities. To achieve a better understanding of the genetic contribution to carboplatin resistance or toxicities, lymphoblastoid ...
Shukla Sunita J +5 more
doaj +1 more source
Pharmaceutics, 2022 Currently, molecular dynamics simulation is being widely applied to predict drug–polymer interaction, and to optimize drug delivery systems. Our study describes a combination of in silico and in vitro approaches aimed at improvement in polymer-based ...
Maria B. Sokol +9 more
doaj +1 more source
Molecular Oncology, EarlyView.Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang +12 more
wiley +1 more source
European Journal of Case Reports in Internal Medicine, 2023 Drug-induced immune haemolytic anaemia (DIIHA) is a rare but serious complication affecting approximately 1 in 1,000,000 patients, but its incidence might be underestimated due to misdiagnosis.
Pitchaporn Yingchoncharoen +6 more
doaj +1 more source
Metronomic chemotherapy preserves quality of life ensuring efficacy in elderly advanced non small cell lung cancer patients [PDF]
, 2016 Metastatic non small cell lung cancers (NSCLC) are diseases with poor prognosis and platinum-based doublet chemotherapy still remains their standard cure.
DE IULIIS, Francesca +5 more
core +1 more source
Molecular Oncology, EarlyView.Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch +13 more
wiley +1 more source
Bangladesh Journal of Pharmacology, 2015 We investigated dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment on stage II-IV ovarian cancer patients.
Zhenhua Du, Xiaolin Ma
doaj
Synthesis of Cis-Diammine (1,1-cyclobutane dicarboxylate) Platinum(II) [PDF]
Iranian Journal of Chemistry & Chemical Engineering, 2017 Platinum-based anticancer drugs are chemotherapeutic agents to treat cancer. Carboplatin (cis diammine cyclobutane dicarboxylate platinum (II)) is a second generation drug that has less toxic than cisplatin, allowing for high dosages. In the first stage,
Ali Nemati kharat +3 more
doaj
Biomedicines, 2023 Background: Platinum compounds are a group of fundamental chemotherapeutics used in the treatment of solid tumors, but they are burdened by side effects, such as ototoxicity. The objective of this study was to evaluate the incidence of ototoxicity caused
Alberto Romano +8 more
doaj +1 more source